SkinBioTherapeutics PLC Appointment of Joint Broker (0278B)

TIDMSBTX

RNS Number : 0278B

SkinBioTherapeutics PLC

05 January 2018

SkinBioTherapeutics plc

Appointment of Joint Broker

Manchester, UK - 5 January 2018 - SkinBioTherapeutics plc (AIM: SBTX, the "Company"), a life science company focused on skin health, announces the appointment of Northland Capital Partners to act as the Company's Joint Corporate Broker, alongside Turner Pope Investments, with immediate effect.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

-Ends-

For more information, please contact:

 
 SkinBioTherapeutics plc                 Tel: +44 (0) 
  Dr. Cath O'Neill, CEO                   161 468 2760 
  Doug Quinn, CFO 
 Cairn Financial Advisers LLP            Tel: +44 (0) 
  (Nominated Advisor)                     20 7213 0880 
  Tony Rawlinson / Emma Earl / 
  Richard Nash 
 Turner Pope Investments (Joint          Tel: +44 (0) 
  Broker)                                 20 3621 4120 
  Ben Turner / James Pope 
 Northland Capital Partners (Joint       Tel: +44 (0) 
  Broker)                                 20 3861 6625 
  John Howes / Tom Price 
 Instinctif Partners (Media Relations)   Tel: +44 (0) 
  Melanie Toyne-Sewell / Deborah          20 7457 2020 
  Bell                                    [e-mail] 
 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas.

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix(R). The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising GBP4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPBRGDBGGGBGIS

(END) Dow Jones Newswires

January 05, 2018 02:00 ET (07:00 GMT)